nanoComposix Expands Capabilities to Include Drug Manufacturing

SAN DIEGO, June 11, 2019 /PRNewswire/ — nanoComposix, a nanotechnology development and contract manufacturing company, recently received its Drug Manufacturing License from the Food and Drug Branch of the State of California Department of Public Health.  NanoComposix has been manufacturing nanomaterials for biotech clients under cGMPs (QSR, 21 CFR 820) since 2017. The facility includes a qualified ISO 8 cleanroom dedicated to cGMP manufacture of nanomaterial-based medical devices and drugs. As a contract manufacturing organization, the capability of manufacturing drugs in-house ensures nanoComposix’ growing number of clients have the flexibility to utilize one vendor throughout the product life cycle. 

Founder & President Dr. Steve Oldenburg said: “This opens up a new set of capabilities for our clients and allows us to align with our long-term corporate goal of supplying nanotechnology enabled products from concept through commercialization.”

About nanoComposix

Since 2004, nanoComposix has provided development, fabrication, processing and scale-up to accelerate the commercialization of nanomaterial in several applications that include in-vitro diagnostics, therapeutics, devices, plasmonic, and preclinical drugs.  NanoComposix is focused on the development and scale up of cGMP manufacture of colloidal nanomaterials for its customers.

For more information about nanoComposix, please visit nanocomposix.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nanocomposix-expands-capabilities-to-include-drug-manufacturing-300865576.html

SOURCE nanoComposix

Staff

Recent Posts

Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods

Milestone enables GMP manufacturing to accelerate clinical trials and transform global vaccine delivery BRISBANE, Australia…

17 hours ago

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading…

17 hours ago

President Trump’s Cannabis Decision Is Coming – And Why MMJ International Holdings Wins Either Way

12 Month Timeline - How Cannabis Rescheduling Actually Takes EffectAnnouncementPresident signals intent or issues executive…

1 day ago

Accelerating Patient Recruitment and Research Excellence: TrialWire® Supports Endpoints Clinical Trials Day NYC 2025

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment…

2 days ago

Genesis Healthcare Remains Committed to Securing Longterm Stability

The skilled nursing, assisted and senior living provider reiterates dedication to a financial restructuring process…

2 days ago